GALC and synucleinopathy: Given the evidence that GALC deficiency may play a contributing factor for the development of synucleinopathies in a subset of patients (Marshall and Bongarzone, 2016; Chang et al., 2017; Li et al., 2018; Marshall et al., 2018a), this therapy may have utility in these forms of late-onset synucleinopathies, beyond its use in KD.